$Q32 Bio (QTTB.US)$ Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting Friday, 28th February at 9:00 am -- Oral presentation to highlight Phase 2a Part A results of the randomized, placebo-controlled SIGNAL-AA clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata (AA) -- WALTHAM, Mass., Feb. 28, 2025 /PRNewswire/ -- Q32 ...
Smokey93
OP
Tree_in_Sydney
:
good potiental. did a big drop off bad news. but just hit the reversal trend! still a Bio stock analysts say worth 10-15. time to bounce back. but the swings big. very very low float and shares available.
Warren Buff
OP
Smokey93
:
after reading the bad news, its not THAT bad that it could cause an 80% drop on the price. I personally think that the market overreacted a bit too much
$Q32 Bio (QTTB.US)$ $Q32 Bio (QTTB.US)$ reverse trend? get it before it's talked about, after a 50 percent gain day.... 22 percent shorts float.... they had some horrible news on december 11th. did there dip. most analysts have downgraded targets from $40-$50 down to $10-$20. which is still considerably higher than $4. looks to have consolidated around the 3-4. breaking the downward trend. I will be buying before the burst this week.... low shares low float. ... risky business is the name of the...
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Q32 Bio Stock Forum
Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting
Friday, 28th February at 9:00 am
-- Oral presentation to highlight Phase 2a Part A results of the randomized, placebo-controlled SIGNAL-AA clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata (AA) --
WALTHAM, Mass., Feb. 28, 2025 /PRNewswire/ -- Q32 ...
$Q32 Bio (QTTB.US)$
has options
nfa
$Q32 Bio (QTTB.US)$
$Richtech Robotics (RR.US)$
$SEALSQ Corp (LAES.US)$
$XTI Aerospace (XTIA.US)$
$MicroCloud Hologram (HOLO.US)$
$Q32 Bio (QTTB.US)$ reverse trend? get it before it's talked about, after a 50 percent gain day.... 22 percent shorts float.... they had some horrible news on december 11th. did there dip. most analysts have downgraded targets from $40-$50 down to $10-$20. which is still considerably higher than $4. looks to have consolidated around the 3-4. breaking the downward trend. I will be buying before the burst this week.... low shares low float. ... risky business is the name of the...
Worse than placebo for Eczema, ouch
Alopecia worked well, but probably people were looking for the eczema market?
No comment yet